TABLE 1

Patient Characteristics, PET/CT Findings, and Outcome

Patient characteristics								PET/CT evaluation							Outcome
Patient no.	Age (y)			Prognosis (IGCCCG)	TM (baseline)				Baseline		Early response, ΔSUV_mean (%)	After therapy			Treatment result	MIB-1 index (%)		Follow-up (d)
Patient no.	Age (y)	Histology	Regime	Prognosis (IGCCCG)	AFP	β-HCG	LDH	Tracer	SUV_max	SUV_mean	Early response, ΔSUV_mean (%)	SUV_max	SUV_mean	CT/TM	Treatment result	MIB-1 index (%)	R/NR	Follow-up (d)	Relapse
1	45	NS	HD-CE	Intermediate	196	175	253	¹⁸F-FDG	23.7	14.8	−89	1.6	1.5	PRm−	CR	NA	R	1,337	No
								¹⁸F-FLT	11.4	7.1	−79	1.6	1.2
2	31	NS	HD-PEI	Poor	34,384	143	360	¹⁸F-FDG	18.3	11.6	−67	4.4	2.6	SD	VC	1	NR	293	Yes
								¹⁸F-FLT	9.8	9.7	−70	2.6	1.3
3	48	NS	PEB	Intermediate	4,563	9.8	236	¹⁸F-FDG	12.4	5.5	−56	4.2	2.3	SD	TER	20	NR	1,030	No
								¹⁸F-FLT	6.3	2.8	−14	3.4	1.4
4	30	NS	HD-PEI	Poor	1,179	59,876	511	¹⁸F-FDG	5.1	2.9	−14	2.5	1.4	PRm−	VC	70	NR	238	Yes
								¹⁸F-FLT	4.6	2.0	−35	1.9	0.7
5	39	NS	HD-PEI	Poor	50	890	3,650	¹⁸F-FDG	14.8	9.6	−75	1.8	1.4	CR	CR	NA	R	325	No
								¹⁸F-FLT	6.6	3.4	−24	2.3	1.0
6	46	NS	HD-PEI	Poor	688	0.54	1,235	¹⁸F-FDG	15.2	9.0	−29	1.9	1.1	PRm−	NEC	<1	R	540	No
								¹⁸F-FLT	1.0	1.0	NA	NA	NA
7	41	S	PEB	Good	1	2	2,293	¹⁸F-FDG	14.5	8.5	−74	1.7	1.5	PRm−	PRm-	NA	R	206	No
								¹⁸F-FLT	5.6	4.7	−64	2.0	1.2
8	41	NS	TIP	Intermediate	420	5,612	564	¹⁸F-FDG	21.0	15	−86	2.7	1.2	PRm−	DoD	NA	NR	241	Yes
								¹⁸F-FLT	5.4	3.0	−67	1.9	0.9
9	22	NS	HD-PEI	Poor	21,497	3.5	248	¹⁸F-FDG	12.0	7.7	−55	2.3	1.2	PRm−	NEC	<1	R	683	No
								¹⁸F-FLT	5.4	3.2	−43	2.1	1.3
10	34	NS	HD-PEI	Poor	1,787	38,300	514	¹⁸F-FDG	13.5	6.1	−62	2.7	1.2	PRm−	NEC	<1	R	324	No
								¹⁸F-FLT	5.2	2.6	−73	2.1	1.3
11	36	NS	PEB	Intermediate	989	6,135	573	¹⁸F-FDG	10.0	5.7	−79	2.1	1.0	PRm+	TER	2	NR	542	No
								¹⁸F-FLT	2.9	1.7	−53	1.5	0.8

IGCCCG = International Germ Cell Cancer Collaborative Group; TM = tumor marker; AFP = α-fetoprotein (ng/mL); β-HCG = β-human chorionic gonadotropin (U/L); LDH = lactate dehydrogenase (U/L); R = responder; NR = nonresponder; NS = nonseminoma; HD-CE = high-dose carboplatin and etoposide; PRm− = marker-negative partial remission; CR = complete remission; NA = not applicable; HD-PEI = high-dose cisplatin, etoposide, and ifosfamide; SD = stable disease; VC = vital carcinoma; PEB = cisplatin, etoposide, and bleomycin; TER = teratoma; NEC = necrosis; TIP = paclitaxel, ifosfamide, and cisplatin; S = seminoma; DoD = death of disease; PRm+ = marker-positive partial remission.